Write the gate before you see the results
In banking, I worked with model risk teams that expected the purpose, validation approach and withdrawal conditions to be clear before a model went into use. I did not always enjoy the extra review, but I understood its value when a result was disputed. For an enterprise AI pilot, I want the same agreement in proportion to the work: what would justify expanding it, what needs repair, and what would make us stop?
Without one, a polished demo can overshadow persistent failures, or a single awkward answer can kill a useful project. I tell executives to measure in weeks. A 90-day pilot with a gate defined on day one tells you more than a year of vendor demos, because it forces a decision instead of a narrative.
Define acceptance in business terms
Specify the evaluation population, representative questions and review method. Record what counts as an acceptable answer, a useful clarification and an unacceptable disclosure. Set thresholds from the current process and the organization's risk appetite. A generic accuracy target borrowed from an industry report cannot substitute for a task-specific judgment.
Include operating conditions. A system can answer well while requiring unsustainable intervention. Name the expected level of human review, source freshness requirements and the cost envelope. Expansion should depend on whether the whole workflow is viable, not on whether the model occasionally produces a brilliant answer.
Decide up front who sits at the gate. I want the business owner, the data owner, someone from risk or compliance and one person who did not build the pilot. In healthcare and life sciences, add the clinical or quality reviewer who would answer for a bad outcome. If those people are not named before the pilot starts, the gate will be staffed by the team that most wants to continue.
Keep non-negotiable failures out of the average
Some failures should never be averaged away. An inappropriate disclosure of customer financial data or protected health information, or an unauthorized action, is not offset by a hundred correct routine answers. Define these cases explicitly and the response to each: disable a capability, narrow access, investigate or restart evaluation after remediation.
Other outcomes are healthy signals. An assistant that asks for clarification when a metric is ambiguous is behaving correctly. An unsupported question may reveal a useful boundary rather than a defect. Classify outcomes so the team does not reward confident answers at the expense of trustworthy behavior.
Look for patterns. A missing source field, a stale report and a misunderstood question need different fixes. The gate should show whether remaining problems have a practical remedy and whether that remedy fits the business case.
Make scale, revise and stop genuinely different
Scaling means expanding one defined dimension: users, question types, sources or actions. Say which one, and which controls must be reevaluated. Adding users to a stable read-only workflow is a different decision from letting the system update records. Calling both “phase two” hides the consequence.
Revising means changing the approach while keeping a testable objective. Narrow the question set, fix source definitions or replace a fragile integration, but give the revision a deadline and a new evidence target. Otherwise it becomes an indefinite pilot that can never succeed or fail.
Stopping means closing the experiment responsibly. Remove unneeded access, preserve the evidence and explain what was learned. A stopped pilot that prevented a larger unsuitable investment is a good outcome, not wasted work, and it should not be relabeled a success to protect the narrative.
Match the gate to the institution and record it plainly
Use the organization’s existing approval requirements to decide who attends the gate. A sponsor and business reviewer may be enough for a narrow internal experiment; customer-facing or clinical work may need independent review before expansion. Record which approvals apply to the proposed next step. Passing the pilot should not be interpreted as permission for a different audience, data scope or action.
Whatever the size, produce a short record: what was evaluated, what the evidence showed, what remains uncertain and what happens next, with the configuration and date. Ask an independent business reviewer to challenge the recommendation using the hardest examples. Then tell participants plainly what changed and what remains experimental, so continued access is never mistaken for broad approval.